Status:
COMPLETED
Tailoring Varenicline to Individual Needs (TVIN Study)
Lead Sponsor:
Queen Mary University of London
Conditions:
Tobacco Dependence
Smoking Cessation
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Varenicline is a partial nicotinic agonist which acts on alpha4 beta2 nicotinic receptors. It is presumed to alleviate withdrawal discomfort, but also to diminish rewarding effects of cigarettes. The ...
Eligibility Criteria
Inclusion
- Smoker seeking treatment
- Aged 18 and over
- Consenting to take part
- Report little or no change in enjoyment of cigarettes and/or nausea
Exclusion
- Pregnant or breastfeeding
- Have severe kidney disease
- Have severe heart problems
- Have a current psychiatric illness
- Are unable to fill in questionnaires in English
- Have an allergy to varenicline
- Are currently involved in another clinical trial
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01206010
Start Date
July 1 2011
End Date
February 1 2013
Last Update
April 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tobacco Dependence Research and Treatment Unit
London, United Kingdom, E1 2JH